Assessing the influence of GLUT5 overexpression on the tumor microenvironment and its role in tumor immune evasion and exploring it as a diagnostic, prognostic, or early detection biomarker could revolutionize patient management, therapy selection, and outcome prediction. This evidence concerns the gene SLC2A5 and neoplasm.